NCT05007873View on ClinicalTrials.gov

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Chronic Phase Chronic Myelogenous LeukemiaPhiladelphia Chromosome PositiveBCR-ABL1 Positive Chronic Myelogenous LeukemiaBCR-ABL1 Positive
Interventions
DRUG

Dasatinib

Given PO

DRUG

Decitabine and Cedazuridine

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER